Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
NASA's Artemis astronauts enter final preparations for Moon mission - 2Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- 3Figure out How to Keep up with Oral Wellbeing During Pregnancy
- 4This country music star spent years hiding his sexuality. Coming out — and beating addiction — has made his soul feel '20 pounds lighter.'
- 5Gaza receiving over 70,000 cubic meters of water per day, COGAT claims
- People with depression can treat themselves at home with new device
- When will the Epstein files be released — and will they reveal anything new?
- 5 VIP Voice Exhibitions in Energized Movies
- French rapper Gims placed under investigation for 'aggravated money laundering'
- NASA releases stunning first images of Earth taken by the Artemis II astronauts
- Instructions to Adjust Work, Life, and Seeking after a Web based Advertising Degree
- Bahrain cracks down on dissent as war grinds on
- Several injured as man threatens attack on German high-speed train
- Starship success, a private moon landing and more: The top 10 spaceflight stories of 2025
